Thayer Partners’s AbbVie ABBV Stock Holding History

Thayer Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$448K	Buy	1,779 +73	+4%	+$15.7K	0.19%	67
2026 Q1	$371K	Sell	1,706 -14	-0.8%	-$3.11K	0.18%	70
2025 Q4	$393K	Buy	+1,720	New	+$392K	0.19%	65

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Thayer Partners's ABBV Position: Q2 2026 in Review

Thayer Partners increased its AbbVie (ABBV) stake by 4.3% in Q2 2026, buying an estimated $15.7K and bringing the position to 1,779 shares worth $448K. The position accounts for 0.19% of the portfolio, ranked #67.

Thayer Partners first reported a position in ABBV in Q4 2025 and has held it in 3 quarters since. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Thayer Partners held 1,779 shares of AbbVie worth $448K as of Q2 2026.
Thayer Partners bought 73 AbbVie shares in Q2 2026, an estimated $15.7K.
AbbVie made up 0.19% of Thayer Partners's portfolio in Q2 2026, its #67 holding.
Thayer Partners first reported a position in AbbVie in Q4 2025 and has held it in 3 quarters since.
4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Thayer Partners's 13F filing for Q2 2026, filed 31 Jul 2026.